Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the results of a Groupe Francophone Des Myélodysplasies (GFM) phase II study of azacitidine combined with APR-246 in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.